Thank you very much, Madam Chair.
When we were doing the study on national pharmacare, one of the groups that came and presented was CORD. It's an organization that deals with Canadians who are suffering from rare disorders, rare diseases. They talked about some of the difficulties they had in getting treatment or in gaining access to new pharmaceuticals for rare diseases. That was when we were doing the national pharmacare study. We've heard other testimony at the committee dealing with unique diseases and with the problems Canadians have, particularly when they're in a small subset with a disease or disorder.
I think, having talked it through, there's an interest in looking at a study. The motion is as follows:
That, pursuant to Standing Order 108(2), the Committee undertake a study on the barriers to access to treatment and drugs for Canadians affected by rare diseases and disorders in order to develop recommendations on actions that the federal government can take, in partnership with the provinces and territories, to remove these barriers; that the Committee report its findings and recommendations to the House no later than December 31, 2018; and that, pursuant to Standing Order 109, the Committee request that the Government table a comprehensive response to the report.
I'd like to move the adoption of this motion.